Do analysts rate PLUR or ERNA?

Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 665.31%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ernexa Therapeutics is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PLUR or ERNA more profitable?

Ernexa Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% Ernexa Therapeutics N/A -263.74% -151.16%

Is ATOS or ERNA more profitable?

Atossa Genetics' return on equity of -84.91% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -84.91% -72.36% Ernexa Therapeutics N/A -263.74% -151.16%

Does the media prefer ATOS or ERNA?

In the previous week, Ernexa Therapeutics had 3 more articles in the media than Atossa Genetics. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.94 beat Ernexa Therapeutics' score of 0.57 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CLRB or ERNA more profitable?

Ernexa Therapeutics' return on equity of -263.74% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% Ernexa Therapeutics N/A -263.74% -151.16%

Does the media prefer CLRB or ERNA?

In the previous week, Ernexa Therapeutics had 3 more articles in the media than Cellectar Biosciences. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.27 beat Ernexa Therapeutics' score of 0.57 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LSTA or ERNA more profitable?

Lisata Therapeutics' return on equity of -103.54% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% Ernexa Therapeutics N/A -263.74% -151.16%

Does the media favor LSTA or ERNA?

In the previous week, Ernexa Therapeutics had 2 more articles in the media than Lisata Therapeutics. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 3 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 0.63 beat Ernexa Therapeutics' score of 0.57 indicating that Lisata Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lisata Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ernexa Therapeutics (ERNA) Competitors

$3.92 -0.01 (-0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$4.11 +0.19 (+4.95%)

As of 07:59 PM Eastern

Compare

ERNA vs. MRKR, PLUR, ATOS, CLRB, and LSTA

Should you buy Ernexa Therapeutics stock or one of its competitors? MarketBeat compares Ernexa Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ernexa Therapeutics include Marker Therapeutics (MRKR), Pluri (PLUR), Atossa Genetics (ATOS), Cellectar Biosciences (CLRB), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry.

How does Ernexa Therapeutics compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Marker Therapeutics has higher earnings, but lower revenue than Ernexa Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	N/A	N/A	-$12.16M	-$0.61	N/A
Ernexa Therapeutics	$580K	7.91	-$14.08M	-$26.20	N/A

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ernexa Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

In the previous week, Ernexa Therapeutics had 4 more articles in the media than Marker Therapeutics. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.89 beat Ernexa Therapeutics' score of 0.57 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Marker Therapeutics	Very Positive
Ernexa Therapeutics	Positive

Marker Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 719.67%. Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 665.31%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Marker Therapeutics beats Ernexa Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Pluri?

Pluri (NASDAQ:PLUR) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Ernexa Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 665.31%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ernexa Therapeutics is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Ernexa Therapeutics had 4 more articles in the media than Pluri. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 1 mentions for Pluri. Pluri's average media sentiment score of 1.89 beat Ernexa Therapeutics' score of 0.57 indicating that Pluri is being referred to more favorably in the media.

Company	Overall Sentiment
Pluri	Very Positive
Ernexa Therapeutics	Positive

Pluri has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market.

Ernexa Therapeutics has lower revenue, but higher earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	13.21	-$22.58M	-$4.53	N/A
Ernexa Therapeutics	$580K	7.91	-$14.08M	-$26.20	N/A

16.6% of Pluri shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 43.2% of Pluri shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ernexa Therapeutics beats Pluri on 9 of the 16 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Ernexa Therapeutics has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
Ernexa Therapeutics	$580K	7.91	-$14.08M	-$26.20	N/A

Atossa Genetics currently has a consensus price target of $20.33, suggesting a potential upside of 761.58%. Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 665.31%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities analysts clearly believe Atossa Genetics is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Atossa Genetics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market.

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Atossa Genetics' return on equity of -84.91% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

In the previous week, Ernexa Therapeutics had 3 more articles in the media than Atossa Genetics. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.94 beat Ernexa Therapeutics' score of 0.57 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Atossa Genetics beats Ernexa Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Cellectar Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market.

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ernexa Therapeutics has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Ernexa Therapeutics	$580K	7.91	-$14.08M	-$26.20	N/A

Cellectar Biosciences presently has a consensus target price of $11.00, suggesting a potential upside of 354.55%. Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 665.31%. Given Ernexa Therapeutics' higher probable upside, analysts clearly believe Ernexa Therapeutics is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ernexa Therapeutics' return on equity of -263.74% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

In the previous week, Ernexa Therapeutics had 3 more articles in the media than Cellectar Biosciences. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.27 beat Ernexa Therapeutics' score of 0.57 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ernexa Therapeutics beats Cellectar Biosciences on 9 of the 15 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Lisata Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 941.67%. Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 665.31%. Given Lisata Therapeutics' higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ernexa Therapeutics has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	77.17	-$16.59M	-$1.86	N/A
Ernexa Therapeutics	$580K	7.91	-$14.08M	-$26.20	N/A

In the previous week, Ernexa Therapeutics had 2 more articles in the media than Lisata Therapeutics. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 3 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 0.63 beat Ernexa Therapeutics' score of 0.57 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lisata Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lisata Therapeutics' return on equity of -103.54% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

Lisata Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market.

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 9.1% of Lisata Therapeutics shares are held by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Ernexa Therapeutics beats Lisata Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Ernexa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERNA vs. The Competition

Export

Metric	Ernexa Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.58M	$3.08B	$6.91B	$12.18B
Dividend Yield	N/A	2.07%	2.67%	9.42%
P/E Ratio	-0.15	20.21	27.07	23.74
Price / Sales	7.91	369.68	528.19	92.55
Price / Cash	N/A	26.63	26.39	46.67
Price / Book	0.51	4.35	10.47	6.16
Net Income	-$14.08M	$65.94M	$3.60B	$331.26M
7 Day Performance	-27.81%	-1.47%	-1.28%	-0.06%
1 Month Performance	-43.76%	-4.86%	-2.61%	-2.52%
1 Year Performance	-91.96%	10.74%	18.45%	13.95%

Ernexa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERNA Ernexa Therapeutics	3.8023 of 5 stars	$3.92 -0.3%	$30.00 +665.3%	-91.9%	$4.58M	$580K	N/A	10	Short Interest Decrease
MRKR Marker Therapeutics	2.6479 of 5 stars	$1.24 -2.4%	$10.00 +706.5%	-21.8%	$21.17M	$3.55M	N/A	60	Positive News
PLUR Pluri	0.6476 of 5 stars	$1.85 -5.1%	N/A	-65.5%	$21.04M	$1.34M	N/A	150
ATOS Atossa Genetics	2.2389 of 5 stars	$2.43 +1.3%	$20.33 +736.8%	-81.7%	$20.67M	N/A	N/A	8
CLRB Cellectar Biosciences	3.9426 of 5 stars	$2.47 -4.3%	$11.00 +345.3%	-52.7%	$20.62M	N/A	N/A	10	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERNA) was last updated on 7/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. MRKR, PLUR, ATOS, CLRB, and LSTA

How does Ernexa Therapeutics compare to Marker Therapeutics?

Summary

How does Ernexa Therapeutics compare to Pluri?

Summary

How does Ernexa Therapeutics compare to Atossa Genetics?

Summary

How does Ernexa Therapeutics compare to Cellectar Biosciences?

Summary

How does Ernexa Therapeutics compare to Lisata Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. MRKR, PLUR, ATOS, CLRB, and LSTA

How does Ernexa Therapeutics compare to Marker Therapeutics?

Which has preferable valuation & earnings, MRKR or ERNA?

Do institutionals & insiders have more ownership in MRKR or ERNA?

Is MRKR or ERNA more profitable?

Does the media prefer MRKR or ERNA?

Which has more risk & volatility, MRKR or ERNA?

Do analysts rate MRKR or ERNA?

Summary

How does Ernexa Therapeutics compare to Pluri?

Is PLUR or ERNA more profitable?

Do analysts rate PLUR or ERNA?

Does the media prefer PLUR or ERNA?

Which has more risk and volatility, PLUR or ERNA?

Which has stronger earnings and valuation, PLUR or ERNA?

Do institutionals and insiders have more ownership in PLUR or ERNA?

Summary

How does Ernexa Therapeutics compare to Atossa Genetics?

Which has better valuation and earnings, ATOS or ERNA?

Do analysts prefer ATOS or ERNA?

Which has more risk and volatility, ATOS or ERNA?

Do institutionals & insiders hold more shares of ATOS or ERNA?

Is ATOS or ERNA more profitable?

Does the media prefer ATOS or ERNA?

Summary

How does Ernexa Therapeutics compare to Cellectar Biosciences?

Which has more volatility and risk, CLRB or ERNA?

Do institutionals and insiders hold more shares of CLRB or ERNA?

Which has higher earnings & valuation, CLRB or ERNA?

Do analysts prefer CLRB or ERNA?

Is CLRB or ERNA more profitable?

Does the media prefer CLRB or ERNA?

Summary

How does Ernexa Therapeutics compare to Lisata Therapeutics?

Do analysts prefer LSTA or ERNA?

Which has better earnings & valuation, LSTA or ERNA?

Does the media favor LSTA or ERNA?

Is LSTA or ERNA more profitable?

Which has more volatility and risk, LSTA or ERNA?

Do institutionals and insiders hold more shares of LSTA or ERNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools